$PLX
Protalix BioTherapeutics, Inc. Stock $plx

$plx Overview Financials Valuation SEC Filings Company Website

2017 Form 10-K Financial Statement

#000114420418013053 Filed on March 06, 2018

Income Statement

Concept	2017	2016 Q4	2016
Revenue	$19.24M	$2.080M	$9.199M
YoY Change	109.17%		110.79%
Cost Of Revenue	$15.23M	$1.950M	$8.398M
YoY Change	81.36%		1050.41%
Gross Profit	$4.011M	$130.0K	$801.0K
YoY Change	400.75%		-77.96%
Gross Profit Margin	20.85%	6.25%	8.71%
Selling, General & Admin	$11.53M	$3.140M	$9.356M
YoY Change	23.24%	143.41%	28.53%
% of Gross Profit	287.46%	2415.38%	1168.04%
Research & Development	$32.17M	$6.710M	$30.41M
YoY Change	5.78%	-12.86%	22.19%
% of Gross Profit	802.04%	5161.54%	3796.75%
Depreciation & Amortization	$1.920M	$490.0K	$1.983M
YoY Change	-3.18%	-12.5%	-16.33%
% of Gross Profit	47.87%	376.92%	247.57%
Operating Expenses	$43.70M	$8.850M	$39.77M
YoY Change	9.89%	14.94%	23.63%
Operating Profit	-$34.52M	-$8.720M	-$33.16M
YoY Change	4.08%	13.25%	40.11%
Interest Expense	-$47.60M	-$7.970M	-$10.08M
YoY Change	372.22%	816.09%	-384.02%
% of Operating Profit
Other Income/Expense, Net	-$48.92M		$3.987M
YoY Change	-1327.06%		-210.38%
Pretax Income	-$83.44M	-$2.620M	-$29.18M
YoY Change	185.95%	-69.43%	6.96%
Income Tax
% Of Pretax Income
Net Earnings	-$83.44M	-$2.620M	-$29.37M
YoY Change	184.15%	-103.59%	-150.6%
Net Earnings / Revenue	-433.63%	-125.96%	-319.22%
Basic Earnings Per Share
Diluted Earnings Per Share	-$6.37	-$0.25	-$2.88
COMMON SHARES
Basic Shares Outstanding		99.93M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017	2016 Q4	2016
SHORT-TERM ASSETS
Cash & Short-Term Investments	$51.40M	$63.30M	$64.30M
YoY Change	-20.06%	-17.15%	-16.49%
Cash & Equivalents	$51.20M	$63.28M	$63.30M
Short-Term Investments	$200.0K		$1.000M
Other Short-Term Assets	$1.700M	$2.321M	$1.600M
YoY Change	6.25%	39.23%	-48.39%
Inventory	$7.800M	$5.245M	$5.200M
Prepaid Expenses		$416.0K
Receivables	$1.700M	$693.0K	$700.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$62.70M	$71.87M	$71.90M
YoY Change	-12.8%	-16.32%	-16.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.700M	$8.703M	$8.700M
YoY Change	-11.49%	-10.68%	-10.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.900M	$1.700M	$1.700M
YoY Change	11.76%	6.25%	6.25%
Total Long-Term Assets	$9.500M	$10.38M	$10.30M
YoY Change	-7.77%	-8.72%	-9.65%
TOTAL ASSETS
Total Short-Term Assets	$62.70M	$71.87M	$71.90M
Total Long-Term Assets	$9.500M	$10.38M	$10.30M
Total Assets	$72.20M	$82.25M	$82.20M
YoY Change	-12.17%	-15.43%	-15.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.500M	$7.496M	$4.000M
YoY Change	87.5%	35.45%	11.11%
Accrued Expenses	$6.800M	$3.575M	$5.300M
YoY Change	28.3%	127.56%	47.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.900M	$53.90M	$53.90M
YoY Change	-89.05%
Total Short-Term Liabilities	$22.80M	$66.21M	$66.20M
YoY Change	-65.56%	489.34%	491.07%
LONG-TERM LIABILITIES
Long-Term Debt	$51.30M	$23.60M	$23.60M
YoY Change	117.37%	-67.27%	-67.27%
Other Long-Term Liabilities	$27.60M	$4.301M	$2.300M
YoY Change	1100.0%	43.37%	-23.33%
Total Long-Term Liabilities	$78.90M	$25.99M	$25.90M
YoY Change	204.63%	-65.41%	-65.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.80M	$66.21M	$66.20M
Total Long-Term Liabilities	$78.90M	$25.99M	$25.90M
Total Liabilities	$101.7M	$92.20M	$92.20M
YoY Change	10.3%	6.74%	6.71%
SHAREHOLDERS EQUITY
Retained Earnings		-$212.7M
YoY Change		16.02%
Common Stock		$202.7M
YoY Change		4.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$29.50M	-$9.957M	-$10.00M
YoY Change
Total Liabilities & Shareholders Equity	$72.20M	$82.25M	$82.20M
YoY Change	-12.17%	-15.43%	-15.52%

Cashflow Statement

Concept	2017	2016 Q4	2016
OPERATING ACTIVITIES
Net Income	-$83.44M	-$2.620M	-$29.37M
YoY Change	184.15%	-103.59%	-150.6%
Depreciation, Depletion And Amortization	$1.920M	$490.0K	$1.983M
YoY Change	-3.18%	-12.5%	-16.33%
Cash From Operating Activities	-$9.994M	-$7.340M	-$32.10M
YoY Change	-68.86%	90.65%	32.18%
INVESTING ACTIVITIES
Capital Expenditures	$971.0K	$120.0K	$849.0K
YoY Change	14.37%		82.97%
Acquisitions
YoY Change
Other Investing Activities	$5.000K	-$130.0K	$32.00K
YoY Change	-84.38%	-100.33%	-66.67%
Cash From Investing Activities	-$1.119M	-$240.0K	-$967.0K
YoY Change	15.72%	-100.6%	-102.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.419M	19.70M	19.70M
YoY Change	-107.2%	222.42%	196.83%
NET CHANGE
Cash From Operating Activities	-9.994M	-7.340M	-32.10M
Cash From Investing Activities	-1.119M	-240.0K	-967.0K
Cash From Financing Activities	-1.419M	19.70M	19.70M
Net Change In Cash	-12.53M	12.12M	-13.37M
YoY Change	-6.27%	-71.26%	-161.51%
FREE CASH FLOW
Cash From Operating Activities	-$9.994M	-$7.340M	-$32.10M
Capital Expenditures	$971.0K	$120.0K	$849.0K
Free Cash Flow	-$10.97M	-$7.460M	-$32.95M
YoY Change	-66.72%	93.77%	33.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-297932000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-9957000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-31293000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82247000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72214000	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	25992000	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	80755000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	92204000	USD
CY2017Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	5921000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	71867000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	62651000	USD
CY2016Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1677000	USD
CY2017Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1887000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8703000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7676000	USD
CY2016Q4	us-gaap	Assets Assets	82247000	USD
CY2017Q4	us-gaap	Assets Assets	72214000	USD
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4007000	USD
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	7521000	USD
CY2016Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	7496000	USD
CY2017Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	9310000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	837000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	66212000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22752000	USD
CY2016Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	19343000	USD
CY2017Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	46267000	USD
CY2016Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2348000	USD
CY2017Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2586000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	103507000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	202575000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	266495000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-212656000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1721000	USD
CY2015	us-gaap	Revenues Revenues	4364000	USD
CY2016	us-gaap	Revenues Revenues	9199000	USD
CY2017	us-gaap	Revenues Revenues	19242000	USD
CY2015	us-gaap	Cost Of Revenue CostOfRevenue	730000	USD
CY2016	us-gaap	Cost Of Revenue CostOfRevenue	8398000	USD
CY2017	us-gaap	Cost Of Revenue CostOfRevenue	15231000	USD
CY2015	us-gaap	Gross Profit GrossProfit	3634000	USD
CY2016	us-gaap	Gross Profit GrossProfit	801000	USD
CY2017	us-gaap	Gross Profit GrossProfit	4011000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24889000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30412000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32170000	USD
CY2015	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	20025000	USD
CY2016	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	24608000	USD
CY2017	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	28834000	USD
CY2015	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	4864000	USD
CY2016	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	5804000	USD
CY2017	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	3336000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7279000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9356000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11530000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-23670000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-33163000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-36353000	USD
CY2015	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3735000	USD
CY2016	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	4192000	USD
CY2017	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	9725000	USD
CY2015	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	123000	USD
CY2016	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	589000	USD
CY2017	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	188000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3612000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3987000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-48923000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	58037000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-29365000	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	94922390	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	101387704	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	131085958	shares
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-85276000	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.61
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2016	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-29176000	USD
CY2017	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-85276000	USD
CY2015	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	85319000	USD
CY2016	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-189000	USD
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity		USD
CY2015	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.29
CY2016	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.29
CY2017	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.65
CY2015	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.9
CY2016	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.00
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
CY2015	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-27282000	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1325000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	1802000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	988000	USD
CY2015	us-gaap	Depreciation Depreciation	2370000	USD
CY2016	us-gaap	Depreciation Depreciation	1983000	USD
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-124000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-13000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-411000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-523000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1133000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-522000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1873000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2139000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	464000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	849000	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	106000	USD
CY2015	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	96000	USD
CY2016	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	32000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6635000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19695000	USD
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-131000	USD
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	277000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	21607000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-13093000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54767000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76374000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	534000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	337000	USD
CY2017	us-gaap	Depreciation Depreciation	1920000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	40000	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	26014000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-25000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2588000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4902000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	971000	USD
CY2017	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	146000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1419000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	414000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-12118000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-32087000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9994000	USD
CY2015	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	1486000	USD
CY2016	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-11000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24284000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32098000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9994000	USD
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	20000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-512000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-967000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1119000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	39387000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-967000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1119000	USD
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-45000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	362000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2316000	USD
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000	USD
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	9542000	USD
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	445000	USD
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	568000	USD
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2334000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19778424	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	76848199	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23532492	shares
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25601000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27465000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2591000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3838000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2259000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3510000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	485000	USD
CY2015	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	168000	USD
CY2016	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	164000	USD
CY2017	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	166000	USD
CY2015	us-gaap	Postemployment Benefits Period Expense PostemploymentBenefitsPeriodExpense	800000	USD
CY2017	us-gaap	Postemployment Benefits Period Expense PostemploymentBenefitsPeriodExpense	906000	USD
CY2015	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	675000	USD
CY2016	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	675000	USD
CY2016	us-gaap	Postemployment Benefits Period Expense PostemploymentBenefitsPeriodExpense	842000	USD
CY2017Q4	plx	Benefits Payable During Next Five Years BenefitsPayableDuringNextFiveYears	250000	USD
CY2017	plx	Milestone Potential Payable MilestonePotentialPayable	14300000	USD
CY2016	plx	Milestone Payment Amount Paid MilestonePaymentAmountPaid	300000	USD
CY2017	plx	Commitment Amount CommitmentAmount	19200000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2554075	shares
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	130000	USD
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P6M14D
CY2016Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	23846735	shares
CY2013Q3	plx	Debt Instrument Principal Amount Related To Initial Purchaser Overallotment Option DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption	9000000	USD
CY2013Q3	plx	Debt Instrument Convertible Conversion Share Number DebtInstrumentConvertibleConversionShareNumber	173.6593	shares
CY2017	plx	Percentage Of Excess Shares Outstanding PercentageOfExcessSharesOutstanding	0.2	pure
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	693000	USD
CY2016Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	53872000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	26851000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	124000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	144000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124134085	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	143728797	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124134085	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	143728797	shares
CY2015	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet		USD
CY2016	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-6473000	USD
CY2017	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-38061000	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	14063000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-55601000	USD
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	746000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	10873000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6101000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6848000	USD
CY2017	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	21000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	685000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	1315000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1273000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	511000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	645000	USD
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	19681000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	920000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	337000	USD
CY2015	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	529000	USD
CY2016	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	68000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	534000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14000	USD
CY2015	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	48674000	USD
CY2016	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	209000	USD
CY2015	plx	Disposal Group Including Discontinued Operation Share In Collaboration Agreement DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement	5048000	USD
CY2015	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	7697000	USD
CY2016	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	373000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	43634000	USD
CY2015	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	46025000	USD
CY2016	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	-164000	USD
CY2015	plx	Disposal Group Including Discontinued Operation Research And Development Expense DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense	-586000	USD
CY2015	plx	Disposal Group Including Discontinued Operation Grants And Reimbursements Received Or Receivable DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable	545000	USD
CY2015	plx	Disposal Group Including Discontinued Operation Research Development Expense Net DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet	-41000	USD
CY2015	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	564000	USD
CY2016	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	25000	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	18654000	USD
CY2015	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	45420000	USD
CY2016	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-189000	USD
CY2015	us-gaap	Discontinued Operation Provision For Loss Gain On Disposal Net Of Tax DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax	-39899000	USD
CY2015	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	59000	USD
CY2016	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	10000	USD
CY2017	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	-18000	USD
CY2015	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	-18000	USD
CY2016	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	-7000	USD
CY2017	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	21000	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000	USD
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	7000	USD
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-6000	USD
CY2017	plx	Income On Conversion Of Convertible Notes IncomeOnConversionOfConvertibleNotes	116000	USD
CY2017	plx	Issuance Of Shares For Interest Payment Regarding Conversion Of Convertible Notes IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes	2391000	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	750000	USD
CY2015	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	39899000	USD
CY2017	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	10961000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1190000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1386000	USD
CY2016Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1399000	USD
CY2017Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1650000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3575000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4802000	USD
CY2016Q4	plx	Accounts Payable Property And Equipment Suppliers Current AccountsPayablePropertyAndEquipmentSuppliersCurrent	595000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	301000	USD
CY2017Q4	plx	Accounts Payable Property And Equipment Suppliers Current AccountsPayablePropertyAndEquipmentSuppliersCurrent	526000	USD
CY2016Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	226000	USD
CY2015	plx	Proceeds From Issuance Of Common Stock Net Of Expenses ProceedsFromIssuanceOfCommonStockNetOfExpenses	6101000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7496000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9310000	USD
CY2015	plx	Milestone Payment Amount Paid MilestonePaymentAmountPaid	0	USD
CY2015	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	489000	USD
CY2016	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	595000	USD
CY2017	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	526000	USD
CY2015	us-gaap	Notes Issued1 NotesIssued1	4301000	USD
CY2016	us-gaap	Stock Issued1 StockIssued1	6848000	USD
CY2017	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	16263000	USD
CY2015	us-gaap	Interest Paid Net InterestPaidNet	3105000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	3659000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	4854000	USD
CY2016Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3520000	USD
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">c.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Use of estimates in the preparation of financial statements</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	38515000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">l.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Concentration of credit risks and trade receivable</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company’s trade receivables represent amounts to be received from Pfizer, Brazil and Chiesi. The Company does not require Pfizer, Brazil or Chiesi to post collateral with respect to receivables.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	plx	Tax Rate Assumption Related To Deferred Tax Difference Reversal TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal	The Company used tax rates of 39%, 24% and 23%.
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	207000000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4301000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5051000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	34304000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	35141000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.39	pure
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	395000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1802000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	988000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	337000	USD
CY2006Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	13841655	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1909000	shares
CY2017Q2	plx	Stockholders Approval Description For Common Stock Issuance StockholdersApprovalDescriptionForCommonStockIssuance	the issuance of shares in excess of 20% of its outstanding shares. On April 12, 2017, the Companys stockholders approved the issuance of shares of the Companys Common Stock in excess of 20% of the Companys outstanding shares of Common Stock to settle conversion requests and pay interest on the Companys issued 7.5% convertible notes.
CY2017Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	215000	USD
CY2017	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	11239641	shares
CY2015	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	-18000	USD
CY2016	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	-7000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	675000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	213000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2017Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	9500000	USD
CY2016Q4	plx	Other Assets Institutions Current OtherAssetsInstitutionsCurrent	333000	USD
CY2017Q4	plx	Other Assets Institutions Current OtherAssetsInstitutionsCurrent	394000	USD
CY2016Q4	us-gaap	Prepaid Royalties PrepaidRoyalties	1046000	USD
CY2017Q4	us-gaap	Prepaid Royalties PrepaidRoyalties	195000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	477000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	623000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	416000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	433000	USD
CY2016Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	327000	USD
CY2016Q4	plx	Other Assets Sundry Current OtherAssetsSundryCurrent	49000	USD
CY2017Q4	plx	Other Assets Sundry Current OtherAssetsSundryCurrent	74000	USD
CY2017	plx	Milestone Payment Amount Paid MilestonePaymentAmountPaid	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	11335000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	47033000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58368000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42035000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		USD

Files In Submission

Name	View Source	Status
0001144204-18-013053-index-headers.html	Edgar Link	pending
0001144204-18-013053-index.html	Edgar Link	pending
0001144204-18-013053.txt	Edgar Link	pending
0001144204-18-013053-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
plx-20171231.xml	Edgar Link	completed
plx-20171231.xsd	Edgar Link	pending
plx-20171231_cal.xml	Edgar Link	unprocessable
plx-20171231_def.xml	Edgar Link	unprocessable
plx-20171231_lab.xml	Edgar Link	unprocessable
plx-20171231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv486893_10k.htm	Edgar Link	pending
tv486893_ex10-16.htm	Edgar Link	pending
tv486893_ex23-1.htm	Edgar Link	pending
tv486893_ex31-1.htm	Edgar Link	pending
tv486893_ex31-2.htm	Edgar Link	pending
tv486893_ex32-1.htm	Edgar Link	pending
tv486893_ex32-2.htm	Edgar Link	pending
tv486893_img1.jpg	Edgar Link	pending
tv486893_img2.jpg	Edgar Link	pending
tv486893_img3.jpg	Edgar Link	pending
tv486893_img4.jpg	Edgar Link	pending
tv486893_img5.jpg	Edgar Link	pending
tv486893_img6.jpg	Edgar Link	pending
tv486893_img7.jpg	Edgar Link	pending
tv486893_img8.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLX
Protalix BioTherapeutics, Inc. Stock $plx

2017 Form 10-K Financial Statement

#000114420418013053 Filed on March 06, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX Protalix BioTherapeutics, Inc. Stock $plx

2017 Form 10-K Financial Statement

#000114420418013053 Filed on March 06, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX
Protalix BioTherapeutics, Inc. Stock $plx